These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29991024)

  • 1. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
    Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
    Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
    Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
    Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
    Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
    Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib.
    Fazio N; Kulke M; Rosbrook B; Fernandez K; Raymond E
    Target Oncol; 2021 Jan; 16(1):27-35. PubMed ID: 33411058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
    Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
    Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
    Valle JW; Borbath I; Rosbrook B; Fernandez K; Raymond E
    Future Oncol; 2019 Apr; 15(11):1219-1230. PubMed ID: 30701988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
    Blumenthal GM; Cortazar P; Zhang JJ; Tang S; Sridhara R; Murgo A; Justice R; Pazdur R
    Oncologist; 2012; 17(8):1108-13. PubMed ID: 22836448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study.
    Sato K; Toyoshima Y; Moriyama S; Endo Y; Ito T; Ohki E
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):201-207. PubMed ID: 30413868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
    Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.
    Rinzivillo M; Fazio N; Pusceddu S; Spallanzani A; Ibrahim T; Campana D; Marconcini R; Partelli S; Badalamenti G; Brizzi MP; Catena L; Schinzari G; Carnaghi C; Berardi R; Faggiano A; Antonuzzo L; Spada F; Gritti S; Femia D; Gelsomino F; Bongiovanni A; Ricci S; Brighi N; Falconi M; Delle Fave G; Panzuto F
    Pancreatology; 2018 Mar; 18(2):198-203. PubMed ID: 29361429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
    Ito T; Okusaka T; Nishida T; Yamao K; Igarashi H; Morizane C; Kondo S; Mizuno N; Hara K; Sawaki A; Hashigaki S; Kimura N; Murakami M; Ohki E; Chao RC; Imamura M
    Invest New Drugs; 2013 Oct; 31(5):1265-74. PubMed ID: 23269537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
    Grande E; Rodriguez-Antona C; López C; Alonso-Gordoa T; Benavent M; Capdevila J; Teulé A; Custodio A; Sevilla I; Hernando J; Gajate P; Molina-Cerrillo J; Díez JJ; Santos M; Lanillos J; García-Carbonero R
    Oncologist; 2021 Nov; 26(11):941-949. PubMed ID: 34190375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib-Induced Hypothyroidism and Survival in Pancreatic Neuroendocrine Tumors.
    Mathew A; Führer D; Lahner H
    Horm Metab Res; 2021 Dec; 53(12):794-800. PubMed ID: 34891209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.
    Wachuła E; Ćwikła JB; Rogowski W; Boratyn-Nowicka A; Szabłowska-Siwik S; Piątek M; Zemczak A; Michalik B; Jarząb B; Nawrocki S; Kos-Kudła B
    Endokrynol Pol; 2014; 65(6):472-8. PubMed ID: 25554616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
    Faivre S; Niccoli P; Castellano D; Valle JW; Hammel P; Raoul JL; Vinik A; Van Cutsem E; Bang YJ; Lee SH; Borbath I; Lombard-Bohas C; Metrakos P; Smith D; Chen JS; Ruszniewski P; Seitz JF; Patyna S; Lu DR; Ishak KJ; Raymond E
    Ann Oncol; 2017 Feb; 28(2):339-343. PubMed ID: 27836885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.
    Ishak KJ; Rael M; Hicks M; Mittal S; Eatock M; Valle JW
    J Comp Eff Res; 2018 Oct; 7(10):947-958. PubMed ID: 30168349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.